Please check the following:
- {{x.value}}
FREE membership
FREE membership
Join Intelligent Investor today
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
Please enter the 5 digit verification code sent to "{{user.DayPhone}}" Change number
We cannot send you a verification code via SMS to "{{user.DayPhone}}" Change number
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
Please enter your mobile number and press send to receive a text message with a verification code.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
Thank you
We have sent you an email with the details of your registration.
Purchase order
Sign up
Log in
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Log in
Upgrade Today
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
{{eventFunction.Name}}
{{eventFunction.EventTypeName}}
{{eventFunction.StartDate}}
{{eventFunction.EventTimings}}
{{eventFunction.VenueName}}
{{ t.Cost === 0 ? "FREE" : "$" + t.Cost.toFixed(2) }}
Quantity *
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
Congratulations!
You now have free access to InvestSMART, we look forward to helping you on your financial journey.
You now have access to Free Eureka Report Insights, We look forward to helping you on your financial journey.
You now have access to Intelligent Investor Free Insights. We look forward to helping you build a market beating stock portfolio.
Looking for more…
Intelligent Investor Membership
15-day Free Trial
- Indepth analysis of ASX listed shares
- BUY, Hold and Sell Recommendations
- Ideas Lab
- Special Reports
No thanks
Looking for more…
Eureka Report Membership
15-day Free Trial
- Alan Kohler’s Weekend Briefing
- Interviews with CEO’s & top influencers
- Money Cafe and Talking Finance
- Super Advice and Q&A with Ask Alan
No thanks
Chimeric Therapeutics Limited (ASX: CHM) - Share Price and Research
Current share price for CHM : $0.033 0.001 (2.94%)
Chimeric Therapeutics Limited (CHM), an ASX-listed company, is a clinical stage cell therapy company and an Australian leader in cell therapy and is is focused on bringing the promise of cell therapy to life for more patients with cancer. Chimeric's team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the innovative and promising cell therapies. Chimeric currently has a diversified portfolio that includes two autologous CAR T cell therapies and allogeneic NK cell therapies
CHM General Information +
| ASX Code | CHM |
| Website | http://www.chimerictherapeutics.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 28 |
| CHM Share Price | $0.033 |
| Day High | $0.035 |
| Day Low | $0.032 |
| Last Close | $0.034 |
| CHM Share Price Movement | $0.00 ( 2.94% ) |
Prices as at 16:40, 16 Apr 2024
+Security prices are delayed by at least 20 minutes and are indicative only.
CHM Related Research
Chimeric Therapeutics Limited (CHM) Upcoming Dividends & Yields
There are no dividends for Chimeric Therapeutics Limited (CHM). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Chimeric Therapeutics Limited (CHM) Recent ASX Announcements
| Headline | Annoucement date/time+ | Price at announcement+ | Current price+ | Price 7D Avg | Gain/Loss |
|---|---|---|---|---|---|
| Change of Director's Interest Notice PH | 8 Apr 2024 5:03PM | $0.032 | $0.033 | $0.032 | risen by 3.13% |
| Change of Director's Interest Notice PH | 8 Apr 2024 5:00PM | $0.032 | $0.033 | $0.032 | risen by 3.13% |
| US patent allowed for CHM 0201 (CORE-NK) technology | 5 Apr 2024 8:50AM | $0.030 | $0.033 | $0.032 | risen by 10% |
- + Company announcements and prices are delayed by at least 20 minutes. Prices are indicative only.
See all ASX announcements from Chimeric Therapeutics Limited (CHM) or use our ASX Announcements tool to search for announcements across all ASX-listed securities.
CHM Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2023A | -$25.50 | -$5.90 | 33.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2022A | -$15.90 | -$4.40 | -44.80% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2021A | -$15.11 | -$8.00 | 0.00% | 0.00 | 0.00 | 0.00% | 0.0% |
CHM Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2021 A | 2022 A | 2023 A | 2021 A | 2022 A | 2023 A | 2021 A | 2022 A | 2023 A | ||
| Chimeric Therapeutics (CHM) | $29M | 0.3326 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| CSL (CSL) | $134,610M | -0.0712 | 0.1072 | 0.1864 | 40.7678 | 36.8209 | 31.0362 | 1.28% | 1.20% | 1.35% |
| Clinuvel Pharmaceuticals (CUV) | $762M | 0.4665 | 0.2049 | 0.1566 | 25.7191 | 21.3453 | 18.4556 | 0.33% | 0.46% | 0.53% |
| Mesoblast (MSB) | $947M | -0.1037 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals (TLX) | $4,266M | -1.3767 | 0.0000 | 0.0000 | 102.2979 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
CHM Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 2.95 | 0.00 |
| Market | 0.52 | 15.00 | 1.11 | 1.02 |
| Sector | 1.27 | 21.40 | 1.95 | 0.98 |
CHM Directors
| Name | Position | Start Date |
|---|---|---|
| Ms Jennifer Chow | Chief Executive Officer, Managing Director | 30 Aug 2021 |
| Mr Phillip Hains | Chief Financial Officer, Joint Company Secretary, Non Executive Director | 12 Jul 2023 |
| Mr Paul Alex Hopper | Founder, Executive Chairman, Executive Director | 2 Feb 2020 |
| Dr Lesley Russell | Non-Executive Director | 28 Aug 2020 |
| Mr Eric Sullivan | Non-Executive Director | 30 Aug 2023 |
Chimeric Therapeutics Limited (CHM) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 14 Dec 2023 | CHOW, Jennifer | Issued | Indirect Shares | 8,643,603 | $0.035 | $302,526.105 |
| 7 Dec 2023 | HAINS, Phillip | Issued | Indirect Shares | 3,571,429 | $0.028 | $100,000.012 |
| 12 Jul 2023 | MATCHAM, George | Issued | Direct Shares | 1,086,956 | $0.046 | $49,999.976 |
See all changes in directors' interest & trades for Chimeric Therapeutics Limited (CHM) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
CHM Management
| Name | Position |
|---|---|
| Eliot Bourk | Chief Business Officer |
| Jason Litten | Chief Medical Officer |
| Nathan Jong | Joint Company Secretary |
CHM Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Chimeric Therapeutics Limited (CHM). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 94,137,432 (17.78%) | Paul Hopper |
CHM Calendar of Events
| Date | Event |
|---|---|
| 27 February 2025 | Report (Interim) |
| 26 September 2024 | Report (Annual) |
| 29 August 2024 | Report (Prelim) |
FAQs about Chimeric Therapeutics Limited (CHM)
What is the current share price of Chimeric Therapeutics Limited (CHM)?
Chimeric Therapeutics Limited's (CHM) current share price is $0.03. This constitutes a price movement of 3.13% when compared to the share price 7 days ago and is -54.17% below CHM's 12-month high of $0.07 per share. Prices are delayed by at least 20 minutes.
What is the share price movement for Chimeric Therapeutics Limited (CHM)?
Relative to the previous close share price of $0.03, Chimeric Therapeutics Limited's (CHM) current share price of $0.03 constitutes a movement of $0.00 or -2.94%. Chimeric Therapeutics Limited's (CHM) share price movement is 3.13% when compared to 7 days ago and is -54.17% below CHM's 52-week high of $0.07.
What is the 52-week high share price for Chimeric Therapeutics Limited (CHM)?
Chimeric Therapeutics Limited's (CHM) 52-week high is $0.07 which was reached on 27 Apr 2023. Relative to this, CHM's current share price of $0.03 constitutes a -$0.04 or -54.17% drop since that high of $0.07 per CHM share.
What is the 52-week low share price for Chimeric Therapeutics Limited (CHM)?
Chimeric Therapeutics Limited's (CHM) 52-week low is $0.02 which was reached on 1 Feb 2024. Relative to this, CHM's current share price of $0.03 constitutes a $0.01 or 37.50% gain since that low of $0.02 per CHM share.
What is the daily average trading volume for Chimeric Therapeutics Limited (CHM)?
Over the last 12 months, Chimeric Therapeutics Limited (CHM) has a daily average trading volume of 1,883,362 CHM shares per day.
What is the dividend yield for Chimeric Therapeutics Limited (CHM)?
Chimeric Therapeutics Limited (CHM) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for CHM is a ratio that tells you the percentage of Chimeric Therapeutics Limited's (CHM) share price that it pays out in dividends each year.
When does Chimeric Therapeutics Limited (CHM) release its next Annual Report?
Chimeric Therapeutics Limited (CHM) will release its next Annual Report on 26 September 2024. Chimeric Therapeutics Limited's (CHM) last annual report was released on 28 Sep 2023. Click here to view Chimeric Therapeutics Limited's (CHM) last annual report.
In which sector is Chimeric Therapeutics Limited (CHM) classified?
Chimeric Therapeutics Limited (CHM) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), Cochlear Limited (COH), ResMed Inc. (RMD), and Fisher & Paykel Healthcare Corporation Limited (FPH).
What is the price-to-earnings (P/E) ratio for Chimeric Therapeutics Limited (CHM)?
The price-to-earnings (P/E) ratio for Chimeric Therapeutics Limited (CHM) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Chimeric Therapeutics Limited's (CHM) share price to its earnings per CHM share.
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
